Fluorouracil
What's New
Last Posted: May 10, 2022
- Xeroderma pigmentosum: an updated review.
Leung Alexander Kc et al. Drugs in context 2022 11 - Biomarkers of Fluorouracil Toxicity: Insight From the PETACC-8 Trial
SM Offer, JAMA Oncology, January 21, 2016 - Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Meulendijks Didier et al. The Lancet. Oncology 2015 Dec (16) 1639-50 - DPYD Genotyping to Predict Adverse Events Following Treatment With Flourouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer
V Boige et al, JAMA Oncology, January 21, 2016 - Pharmacogenomics of fluorouracil -based chemotherapy toxicity.
Matsusaka Satoshi et al. Expert opinion on drug metabolism & toxicology 2015 May (5) 811-21 - Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab
A Post Hoc Analysis of the PETACC-8 Trial
J Taeib et al, JAMA Oncology, January 14, 2016 - Fc?R and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer.
Inoue Yuka, et al. Molecular diagnosis & therapy 2014 10 (5) 541-8 - Genetics of Skin Cancer (PDQ®)–Health Professional Version
- Impact of the MTHFR C677T polymorphism on colorectal cancer in a population with low genetic variability.
Delgado-Plasencia Luciano, et al. International journal of colorectal disease 2013 9 (9) 1187-93 - Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Lévesque Eric, et al. The Journal of pharmacology and experimental therapeutics 2013 4 (1) 95-101 - Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity.
Bosch Tessa M, et al. Molecular diagnosis & therapy 2007 0 (2) 105-8 - Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.
Mattison LK, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2004 4 (8) 2652-8
About RCH PHGKB
Reproductive and Child Health PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to reproductive and child Health...more
Content Summary
Common RCH Related Topics
- Attention Deficit/Hyperactivity Disorder
- Autism
- Birth Defects
- Carrier Testing
- Cerebral Palsy
- Congenital heart defects
- Pregnancy loss
- Developmental Disabilities
- Gestational Diabetes
- Hearing loss
- Neural tube defects
- Infant Mortality
- Infertility
- Learning disability
- Newborn Screening
- Preeclampsia
- Prematurity
- Prenatal Testing
- Stillbirth
- Sudden Infant Death Syndrome
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: